Bank Julius Baer & Co. Ltd, Zurich Seres Therapeutics, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$6.02 - $11.43 $218,218 - $414,326	-36,249 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$5.46 - $22.6 $28,719 - $118,876	-5,260 Reduced 12.67%	36,249 $252,000
Q2 2021 Jul 23, 2021	BUY	$18.46 - $24.36 $207,841 - $274,269	11,259 Added 37.22%	41,509 $990,000
Q1 2021 May 10, 2021	BUY	$17.66 - $28.92 $75,055 - $122,910	4,250 Added 16.35%	30,250 $623,000
Q4 2020 Feb 24, 2021	SELL	$23.25 - $37.73 $3.3 Million - $5.36 Million	-142,072 Reduced 84.53%	26,000 $637,000

Q4 2020 Feb 12, 2021	BUY	$23.25 - $37.73 $3.91 Million - $6.34 Million	168,072 New	168,072 $637,000

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.